Alzheimer's disease (AD) is characterized by the deposition of senile plaques and neurofibrillary tangles in the brain. The presence of the amyloid-b (Ab) peptide in senile plaques seems to play a central role in the neuropathology of AD. Diagnosis of AD involves neuropsychological examinations or magnetic resonance imaging and, to date, a specific diagnostic marker indicating AD has not been found. This study analysed anti-Ab antibodies from the serum of 153 patients with AD using an enzymelinked immunosorbent assay method. The levels of anti-Ab antibody from patients in the control group (n = 193) were compared with those of patients with AD. Our results showed a significantly lower anti-Ab antibody level in patients with AD than in the control group. These results showed that the anti-Ab antibody level in serum could potentially be used to diagnose the presence of AD.
Introduction
Dementia due to degenerative brain disease is a major public health concern. Alzheimer's disease (AD) is the most common form of dementia 1 and its prevalence is rapidly increasing with the ageing society, thus necessitating the need for early diagnosis and prevention. However, the diagnosis of AD has only been possible through limited methods, such as neuropsychological examination or magnetic resonance imaging (MRI).
Although a simple and convenient diagnostic or screening marker for AD has been needed and sought after for quite some time, a specific diagnostic marker indicating AD has not yet been found. The possible role of autoimmunity in the pathogenesis of AD has been investigated. 2 The pathological hallmarks of AD are the occurrence of plaques in the neural parenchyma and the formation of neuronal tangles. 3 Amyloid-β (Aβ), a heterogeneous 39 -42-amino acid peptide, is the primary constituent of senile MS Song, I Mook-Jung, HJ Lee et al. Serum anti-amyloid-b antibodies and Alzheimer's disease plaques and cerebrovascular amyloid deposits. A recent immunological approach to AD showed that a specific antibody to the Aβ protein exists and is closely related to the pathogenesis of AD. 4 -7 Several potential biochemical markers for AD are currently being investigated, including the plasma Aβ protein, 8 a change in the ratio between Aβ 40 and Aβ 42, 9 the level of tau protein in the cerebrospinal fluid (CSF) 10 and a decrease in the level of anti-Aβ peptide antibodies in the CSF 11 of patients with AD. There have recently been a few reports of lower serum titres of anti-Aβ antibodies in AD patients. 11 -13 Taking these observations into account, this study investigated the usefulness of a simple examination of serum anti-Aβ antibody levels for dementia and whether its levels are related to cognitive impairment in elderly Korean subjects.
Patients and methods

STUDY SUBJECTS
Since 2003, the Ajou University School of Medicine and the Bundang Public Health Centre have been conducting the Ajou-Bundang Cohort (ABC) Study for the Elderly, which is a community-based study of geriatric diseases and an epidemiological research project, as well as a visiting health service. The rationale and design of the ABC study have been previously described. 14 This study was designed to provide clinical evaluation of elderly subjects through a cross-sectional, case-control design. Disproportionate random sampling by cognitive status was also performed. Subjects with AD were randomly selected as the cases and those individuals without cognitive impairment served as controls. Each study participant underwent blood tests, neurological examinations and neuropsychological tests. Clinical evaluations were performed by geriatric neurologists whenever appropriate and to the extent possible for an individual patient. All of the subjects were accompanied by informants who helped provide information relevant to the clinical evaluation. The Mini-Mental State Examination (MMSE) 15, 16 and the Clinical Dementia Rating (CDR) 17, 18 evaluations were used to assess subjects. All those whose dementia ratings were higher than CDR 1 were classified and each patient with AD met the criteria for probable AD, 19 established by the National Institute of Neurological and Communicative Disorders and Stroke and by the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA).
The majority of evaluations were conducted at the Bundang Public Health Centre although, in certain cases, researchers visited the homes of subjects with limited mobility. The Ethical Committee of the Ajou-Bundang Cohort Study for the Elderly approved this study. Before enrolment, all study subjects, or their relatives when necessary, gave their informed consent to participate in the study.
SERUM ANTI-AMYLOID-BETA ANTIBODY ASSAY
The immunoglobulin G (IgG) anti-Aβ 42 antibody levels in serum from all subjects were measured using an enzyme-linked immunosorbent assay (ELISA), according to the method described by So et al. 12 Briefly, ELISA plates were coated with 0.1 µg/well of human Aβ 1 -42 peptide in a 0.1 M bicarbonate-carbonate solution at 4°C overnight. The plates were then washed three times with phosphate-buffered saline (PBS) containing 0.05% (v/v) Tween-20 (PBST) using an auto-washer (Thermo Labsystems, Vantaa, Finland), blocked with 10% fetal bovine serum (FBS) diluted with PBS for 1 h and then washed again three MS Song, I Mook-Jung, HJ Lee et al. Serum anti-amyloid-b antibodies and Alzheimer's disease times. The human serum was then diluted 1:100 with 10% FBS and left for 2 h at room temperature to react and produce an Aβ antibody complex. The plates were then washed five times with PBST and incubated for 1 h at room temperature with a secondary antibody (horseradish peroxidaselabelled anti-rabbit antibody) that was diluted 1:2000 with 10% FBS. The plates were then washed five times with PBST. Finally, 100 µl of a mixture of 3,3,5,5-tetramethylbenzidine for the peroxidase substrate and hydrogen peroxide for the peroxide solution were added to the plates, and 1 M sulphuric acid was added to halt the reaction. The formation of a coloured product indicated the presence of anti-Aβ antibodies and absorbance was measured at a wavelength of 450 nm with an imaging system (Las-1000, Fujifilm Medical Systems, Stanford, Connecticut, USA).
STATISTICAL ANALYSIS
The clinical characteristics of the cases and controls were compared using the Student's t-test for continuous variables and the χ 2 test for categorical variables. An unconditional logistic regression analysis was carried out for the associations between the subjects and all independent variables, and was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). The level of significance of the statistical tests was defined as 0.05. To adjust for the effect of confounding variables, factors potentially associated with AD (P < 0.05) according to the univariate analyses were simultaneously entered into a logistic regression model to assess their independence. Multivariate logistic regression analyses were performed in order to analyse the association between AD and clinical variables. All analyses were performed using SPSS ® software version 10.0 (SPSS Inc., Chicago, Illinois, USA).
Results
A total of 153 subjects with AD were randomly selected as the cases and 193 individuals without cognitive impairment served as the controls. Thus, a total of 346 subjects were selected for clinical evaluation in this study.
The demographic characteristics of the study subjects are shown in Table 1 . There were some demographic differences between the cases and controls. Univariate associations Data are mean ± SD, or percentage (%). * P < 0.05 for cases with AD compared with control subjects. Serum anti-amyloid-b antibodies and Alzheimer's disease between the independent variables and AD are shown in Table 2 . The univariate analysis showed that AD was related to advanced age, the female gender, a lower level of education and a decreased serum level of the anti-Aβ antibody. The results of the multivariate logistic regression analyses are shown in Table 3 . Only two of the independent variables associated with AD in the univariate analysis (i.e. female gender and serum anti-Aβ antibodies) remained significant within the regression model.
Discussion
This study sought to determine the relationship between AD and serum anti-Aβ antibody levels. The major finding of this study was a relationship between AD and a lower serum titre of the anti-Aβ antibodies. Previous studies have explained the mechanism underlying the relationship between serum anti-Aβ antibody levels and cognitive function in AD. 12, 13, 20 Patients with AD showed an unusual decrease in serum levels of the anti-Aβ antibody. The first hypothesis is that normal subjects systemically generate an autoantibody to Aβ, which is eliminated by macrophages and decreases the total quantity of Aβ. The second hypothesis is that Aβ forms a unique antigen-antibody complex in the blood. In contrast to Aβ alone, however, the antigen-antibody complex is too large to penetrate the blood-brain barrier into the MS Song, I Mook-Jung, HJ Lee et al. Serum anti-amyloid-b antibodies and Alzheimer's disease brain. This causes a decrease in the total quantity of Aβ and hinders accumulation of Aβ in the brain. For patients with AD, however, the level of anti-Aβ antibodies decreases considerably and they cannot effectively eliminate Aβ. This means that Aβ remnants can accumulate in the brain leading to the development of dementia. This study found that the cases with AD had lower serum titres of the anti-Aβ antibody than the controls (OR: 2.077, 95% CI: 1.153 -3.742).
The other finding of this study is a gender difference in the incidence of AD. The prevalence of AD is higher in females than in males, even after adjusting for the greater longevity of females and the shorter disease survival time of males. 21 In the present study, AD was associated with the female gender, even after adjustments. Although sex hormones, such as oestrogen, may be involved in the pathophysiology underlying this gender difference, the underlying cause of this difference in cognitive impairment remains unclear.
Our study had some limitations. Since this study is a cross-sectional study, it may have had some limitations in terms of determining the distinct relationship between cognitive impairment and various factors. Further longitudinal research is needed to examine the relationship between cognitive function and variable factors, especially the anti-Aβ antibody. Moreover, most of the study subjects were Korean; therefore, our findings may not be applicable to other racial groups. Further studies will be required to confirm the effects of serum anti-Aβ antibody levels on cognitive function in other racial populations.
In conclusion, a lower serum titre of anti-Aβ antibodies was found in subjects with AD than in the controls. A longitudinal assessment of the elderly is currently underway and will provide a greater understanding of dementia and the natural history of degenerative brain diseases.
